Are Retail-Wholesale Stocks Lagging Maplebear Inc. (CART) This Year?
Maplebear is one of 209 individual stocks in the Retail-Wholesale sector. Collectively, these companies sit at #11 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Maplebear is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CART's full-year earnings has moved 7.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CART has gained about 4.6% so far this year. In comparison, Retail-Wholesale companies have returned an average of 2.1%. As we can see, Maplebear is performing better than its sector in the calendar year.
Another stock in the Retail-Wholesale sector, Prosus N.V. Sponsored ADR (PROSY), has outperformed the sector so far this year. The stock's year-to-date return is 40.2%.
In Prosus N.V. Sponsored ADR's case, the consensus EPS estimate for the current year increased 0.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Maplebear is a member of the Internet - Commerce industry, which includes 38 individual companies and currently sits at #64 in the Zacks Industry Rank. On average, stocks in this group have gained 3.9% this year, meaning that CART is performing better in terms of year-to-date returns. Prosus N.V. Sponsored ADR is also part of the same industry.
Investors with an interest in Retail-Wholesale stocks should continue to track Maplebear and Prosus N.V. Sponsored ADR. These stocks will be looking to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Maplebear Inc. (CART) : Free Stock Analysis Report
Prosus N.V. Sponsored ADR (PROSY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Is Go Hub Capital Berhad's (KLSE:GOHUB) Recent Performance Underpinned By Weak Financials?
With its stock down 6.9% over the past three months, it is easy to disregard Go Hub Capital Berhad (KLSE:GOHUB). We decided to study the company's financials to determine if the downtrend will continue as the long-term performance of a company usually dictates market outcomes. Specifically, we decided to study Go Hub Capital Berhad's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Go Hub Capital Berhad is: 6.1% = RM3.7m ÷ RM60m (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. Another way to think of that is that for every MYR1 worth of equity, the company was able to earn MYR0.06 in profit. View our latest analysis for Go Hub Capital Berhad Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. When you first look at it, Go Hub Capital Berhad's ROE doesn't look that attractive. A quick further study shows that the company's ROE doesn't compare favorably to the industry average of 12% either. Go Hub Capital Berhad was still able to see a decent net income growth of 15% over the past five years. So, there might be other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio. We then compared Go Hub Capital Berhad's net income growth with the industry and found that the company's growth figure is lower than the average industry growth rate of 30% in the same 5-year period, which is a bit concerning. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Go Hub Capital Berhad's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. While the company did pay out a portion of its dividend in the past, it currently doesn't pay a regular dividend. We infer that the company has been reinvesting all of its profits to grow its business. In total, we would have a hard think before deciding on any investment action concerning Go Hub Capital Berhad. While the company has posted decent earnings growth, the company is retaining little to no profits and is reinvesting those profits at a low rate of return. This makes us doubtful if that growth could continue, especially if by any chance the business is faced with any sort of risk. Up till now, we've only made a short study of the company's growth data. You can do your own research on Go Hub Capital Berhad and see how it has performed in the past by looking at this FREE detailed graph of past earnings, revenue and cash flows. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $384.84 · 0.2% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
2025 NBA free agency: Deandre Ayton addition slightly improves Los Angeles Lakers' title odds
The Los Angeles Lakers finally have a new center after agreeing to a two-year deal with free agent and former No. 1 overall pick Deandre Ayton, and oddsmakers have bumped up their odds to win next year's NBA championship as a result. The Lakers moved from 16-1 to 14-1 to win the 2025-26 NBA championship at BetMGM, the seventh-best odds of any team and the fourth-best odds for any Western Conference team behind favorite Oklahoma City (+275), Denver (+700) and Houston (+800). Advertisement "They filled an obvious need with a previously unexpected option," Jeff Sherman, vice president of risk at the Westgate Las Vegas SuperBook told Yahoo Sports via text. "We went from 16-1 to 14-1 for perception purposes. We already have — and will continue to have — Lakers liability." The Lakers made the playoffs as the third seed in the West last season after trading for Luka Dončić in the middle of the season, but lost to the Minnesota Timberwolves in the first round in five games. As of Tuesday morning, the Lakers were the second-biggest title liability at BetMGM behind the Dallas Mavericks.
Yahoo
42 minutes ago
- Yahoo
3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now
During periods of market volatility and economic uncertainty, investors often look for refuge in dependable, dividend-paying stocks. These rare giants provide not only consistent income but also long-term stability. Dividend giants are typically well-established companies with strong cash flows, resilient business models, and a long history of rewarding shareholders, which can help safeguard your portfolio. 3 Overlooked Dividend Aristocrats To Buy in 2025 3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Valued at nearly $328 billion, AbbVie (ABBV) is a U.S.-based biopharmaceutical company focused on treating autoimmune disorders, cancers, neurological conditions, and aesthetic medical needs. Its strong cash flow, innovative research, and diverse portfolio of leading medicines position it as a global leader in both prescription therapeutics and aesthetics. AbbVie has a forward dividend yield of 3.5%, which is higher than the healthcare sector average of 1.58%. While the yield is appealing, a reasonable payout ratio indicates how much of its net income the company distributes as dividends while leaving enough to reinvest in the business. Its forward payout ratio of 46.9% is relatively low, indicating that dividend payments are sustainable and have room to grow. AbbVie is also a Dividend King, having paid and increased dividends for 53 straight years. AbbVie is best known for its blockbuster drug Humira, which treats autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. However, to deal with Humira's patent expiration, the company has expanded its portfolio to include blockbuster drugs such as Skyrizi (for psoriasis and Crohn's) and Rinvoq (for rheumatoid arthritis and ulcerative colitis). In the most recent first quarter, Skyrizi's sales stood at $3.4 billion, up 70.5%, while Rinvoq's were $1.7 billion, up 57.2%. Adjusted earnings increased 6.5% in the quarter. Overall, Wall Street has assigned a 'Moderate Buy' rating to AbbVie stock. Out of 27 analysts covering the stock, 14 have a 'Strong Buy' rating, two suggest a 'Moderate Buy' rating, and 11 recommend a 'Hold' rating. The mean target price for ABBV is $208.88, which is 10% above its current levels. Its high price estimate of $250 implies potential upside of 33% over the next 12 months. AT&T (T) is a major American telecommunications company with a market capitalization of $208 billion. It offers wireless services, internet and broadband services, TV and streaming services, as well as business and enterprise solutions like network connectivity, cybersecurity, and cloud services. AT&T offers an attractive forward dividend yield of 3.85%, which is significantly higher than the communications sector average of 2.6%. Importantly, the company's forward payout ratio has improved to 49.7%, thanks to a simpler business model and strong free cash flow (FCF). In the first quarter, the company generated $3.1 billion in FCF, paying out dividends totaling $1.1 billion. Adjusted earnings per share rose by 6.3% in Q1. Furthermore, it expects to generate more than $16 billion in FCF by 2025, which should support dividend payouts. Overall, Wall Street rates AT&T stock as a "Moderate Buy.' Of the 28 analysts covering the stock, 17 recommend a "Strong Buy,' three recommend a 'Moderate Buy,' seven rate it a "Hold,' and one suggests a 'Strong Sell.' Currently, the stock is trading close to its average analyst target price of $29.21. Its high price target of $34, however, represents upside potential of 17.5% over the next 12 months. Valued at $45 billion, Target (TGT) is a major American retail company. Target is known for its low prices, trendy private-label brands, and excellent in-store and online shopping experiences. It also provides same-day delivery and curbside pickup. Target is part of the elite group of Dividend Aristocrats, a group of S&P 500 Index ($SPX) companies that have increased their dividends for at least 25 consecutive years. Target has raised its dividend annually for over 54 consecutive years as of 2025, also putting it in the even more exclusive Dividend Kings club. It recently increased its dividend by 1.8%. The company pays an attractive dividend yield of 4.4%, which is significantly higher than the consumer staples average of 1.9%. Behind every reliable dividend payer is a strong financial engine. While consumer spending can fluctuate, Target's business model enables it to adapt quickly. During a recession, consumers often migrate from premium retailers to value-oriented stores, giving Target a competitive edge. Target's adjusted earnings for the first quarter increased 11.8% to $2.27 per share. The company's payout ratio is within a sustainable range of 56.8%. This means Target has enough room to continue rewarding shareholders while reinvesting in its operations. Overall, Wall Street rates Target stock as a "Moderate Buy.' Of the 34 analysts covering the stock, eight recommend a "Strong Buy,' three say it is a 'Moderate Buy,' 21 rate it a "Hold,' and two suggest a 'Strong Sell.' Based on its average analyst target price of $110.25, the stock has upside potential of 10.9% from current levels. Plus, its high price target of $175 represents upside potential of 77.4% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
